Shire PLC (SHPG) Shares Bought by Federated Investors Inc. PA

Federated Investors Inc. PA grew its holdings in shares of Shire PLC (NASDAQ:SHPG) by 38.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,153 shares of the biopharmaceutical company’s stock after acquiring an additional 2,560 shares during the quarter. Federated Investors Inc. PA’s holdings in Shire PLC were worth $1,513,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. iAB Financial Bank boosted its position in shares of Shire PLC by 8.9% during the 2nd quarter. iAB Financial Bank now owns 6,340 shares of the biopharmaceutical company’s stock valued at $1,048,000 after acquiring an additional 520 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Shire PLC by 6.5% during the 2nd quarter. Marshall Wace LLP now owns 538,704 shares of the biopharmaceutical company’s stock valued at $88,886,000 after acquiring an additional 32,813 shares during the last quarter. Addenda Capital Inc. boosted its position in shares of Shire PLC by 3.2% during the 2nd quarter. Addenda Capital Inc. now owns 5,089 shares of the biopharmaceutical company’s stock valued at $731,000 after acquiring an additional 160 shares during the last quarter. Gamco Investors INC. ET AL boosted its position in shares of Shire PLC by 15.2% during the 2nd quarter. Gamco Investors INC. ET AL now owns 6,904 shares of the biopharmaceutical company’s stock valued at $1,141,000 after acquiring an additional 912 shares during the last quarter. Finally, Checchi Capital Advisers LLC boosted its position in shares of Shire PLC by 18.2% during the 2nd quarter. Checchi Capital Advisers LLC now owns 1,467 shares of the biopharmaceutical company’s stock valued at $242,000 after acquiring an additional 226 shares during the last quarter. Hedge funds and other institutional investors own 19.13% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Shire PLC (SHPG) Shares Bought by Federated Investors Inc. PA” was originally published by Stock Observer and is owned by of Stock Observer. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.thestockobserver.com/2017/09/13/shire-plc-shpg-shares-bought-by-federated-investors-inc-pa.html.

A number of analysts have recently issued reports on SHPG shares. Stifel Nicolaus dropped their price target on Shire PLC from $250.00 to $245.00 and set a “buy” rating for the company in a research report on Friday, June 9th. Jefferies Group LLC reiterated a “buy” rating and set a $216.00 price target (down previously from $239.00) on shares of Shire PLC in a research report on Friday, June 9th. Royal Bank Of Canada set a $221.00 price target on Shire PLC and gave the company a “buy” rating in a research report on Thursday, May 18th. Cantor Fitzgerald set a $222.00 price target on Shire PLC and gave the company a “buy” rating in a research report on Saturday, July 1st. Finally, ValuEngine upgraded Shire PLC from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $220.08.

Shire PLC (NASDAQ SHPG) opened at 162.49 on Wednesday. The stock has a market capitalization of $48.40 billion, a PE ratio of 72.70 and a beta of 1.61. The firm has a 50-day moving average price of $154.29 and a 200-day moving average price of $169.27. Shire PLC has a 52 week low of $139.36 and a 52 week high of $209.22.

Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. Equities research analysts predict that Shire PLC will post $14.93 EPS for the current fiscal year.

The business also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 8th will be paid a $0.1527 dividend. This represents a dividend yield of 0.21%. The ex-dividend date of this dividend is Thursday, September 7th. Shire PLC’s payout ratio is 41.07%.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply